Long-term benefits versus side-effects from bone-targeted therapies for cancer patients: minimizing risk while maximizing benefits. [electronic resource]
Producer: 20150706Description: 420-8 p. digitalISSN:- 1751-4266
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Biomarkers
- Bisphosphonate-Associated Osteonecrosis of the Jaw
- Bone Density Conservation Agents -- administration & dosage
- Bone Neoplasms -- drug therapy
- Bone and Bones -- pathology
- Breast Neoplasms -- drug therapy
- Denosumab
- Diphosphonates -- administration & dosage
- Female
- Humans
- Palliative Care
- Patient Selection
- Quality of Life
- Risk Factors
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.